Introduction
Treatment with 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) reduce serum LDL-cholesterol levels, and atherosclerotic plaques in the carotid artery, coronary artery, and thoracic aorta. [1] [2] [3] [4] However, they have not been shown to reduce atherosclerotic plaques in the abdominal aorta. 4 This discrepancy may be a result of differences in plaque constituents between the thoracic and abdominal aortas. In the thoracic aorta, fatty streaks are common, 5, 6 whereas in the abdominal aorta, fibrous and calcified plaques are frequently observed. 5, 7 Calcified atherosclerotic plaques in the abdominal aorta are closely associated with the incidence of cardiovascular disease. [8] [9] [10] [11] Furthermore, calcified atherosclerotic plaques in the abdominal aorta, as quantified by lateral lumber radiographs, are independent predictors of coronary heart disease 12 and congestive heart failure. 13 Etidronate is a first generation bisphosphonate that has weaker therapeutic ability in inhibiting bone resorption, but stronger ability in preventing ectopic and vascular calcification than that of newer generation bisphosphonates. Some clinical studies have evaluated the regression effect of bisphosphonates on vascular calcification and atherosclerotic plaques. It was found that only etidronate was effective in reducing vascular calcification and atherosclerosis, [14] [15] [16] whereas other bisphosphonates barely had any effects. [17] [18] [19] In the preliminary trial, we assigned the patients with hypercholesterolemia to the atorvastatin group or the atorvastatin plus etidronate combination-therapy group, and treated them for 12 months. As a result, the combination-therapy group and the atorvastatin group reduced maximal vessel wall thickness of the thoracic aorta (-15 % [95% confidence interval [CI] -18.5 to -11.5] and -14 % [95% CI -17.3 to -10.6], respectively). The combination-therapy group reduced maximal vessel wall thickness in the abdominal aorta (-14 % [95% CI -17.5 to -as quantified by lateral lumber radiographs, are independent predictors of coronar ar ry he hear a art t t disease 12 and congestive heart failure. 13 Et Et Etid id idro ro ona ate te te i is s a first generation bisphosph h hon on o a ate that has we we eak a er er t t th h her e apeutic ability in n nhi i ib biting bon ne e r r res s sorp rp pti t on on on, bu bu but t t st stro ro on ng nge er a abil li ity y y in p pr r reve e en nt ntin ing g ec ecto to op pi ic c an an nd d va vasc sc scu ul ular ar r cal al a ci i cific ca cati i tion on on h han an an t t tha ha h t t of of f n n new ewe er er g g gen en ner r rat atio ion n n bi bi bisp sp spho ho hosp sp pho ho ona na nate tes. s. s S Som om ome cl clin in inic ic ical l l s s stu tu udi di ies es es h h hav v ve e ev ev eval al alua ua ate te ted d th th he e egression eff ff fec ec ect t of of of b b bis is sph ph p os os osph ph phon on nat at a e es s s on n n v v vas as ascu cu cula la ar r ca ca alc lc lcif ific ic cat at atio io ion n n an an and d at at athe he hero ro rosc sc scle le l ro ro oti ti ic c c pl pl plaq aq aques. It was s s by guest on April 19, 2017 http://circ.ahajournals.org/ Downloaded from 8.5]), whereas the atorvastatin group did not (-1 % [95% CI -1.9 to -0.1]). However, in this trial, patients were intentionally assigned to either of the two treatment groups according to their bone mineral density levels. 20 In addition, since we did not set the etidronate group into the preliminary trial, we could not evaluate "Is the effectiveness of the combination-therapy due to a single effect from etidronate, an additional one from atorvastatin and etidronate, or a synergistic one from them?".
In this present study, we conducted a randomized controlled trial by recruiting new hypercholesterolemic patients without osteoporosis, in which patients were assigned to the atorvastatin monotherapy, etidronate monotherapy or combination-therapy group, and therapeutic effectiveness was evaluated by the regression of atherosclerotic plaques in the thoracic and abdominal aortas.
Methods

Study design and treatment
This study was designed as a prospective, single center, randomized, open-label, blindedendpoint, parallel group comparison study in order to elucidate differences in the therapeutic effectiveness of three therapy protocols: 20 mg of atorvastatin, 400 mg of etidronate, and both drugs (combination-therapy), on atherosclerotic plaques of the thoracic and abdominal aortas in hypercholesterolemic patients.
We recruited participants from 11 outpatient practices and one health evaluation/promotion center in the Joetsu area, Niigata Prefecture, Japan. All participants were followed up in the Niigata-Rosai Hospital. Hypercholesterolemic patients between the ages of 30
and 80 years were eligible to participate, if they met the eligibility criteria shown in the herapeutic effectiveness was evaluated by the regression of atherosclerotic plaq qu u ues s s in in n t t the he he horacic and abdominal aortas.
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Eligible patients were randomly assigned to the atorvastatin, etidronate or combinationtherapy groups in a 1:1:1 ratio. Randomization was stratified by age and 60-80 years) and sex (male and female) with a permuted block procedure. The randomization list was kept in a secure location at a central coordination center and was not available to any individuals.
Participants in the atorvastatin group received 20 mg of atorvastatin per day consecutively for one year. Participants in the etidronate group received 400 mg of etidronate per day for 14 consecutive days, which was repeated cyclically every three months for one year.
Participants in the combination-therapy group received both drugs for one year.
Using magnetic resonance imaging (MRI), maximal vessel wall thickness, vessel wall area, and lumen area of atherosclerotic lesions in the thoracic and abdominal aortas were determined at baseline, 6 months, and 12 months later.
If participants met the additional treatment criteria, they were initiated on an additional treatment (for details, see the Supplemental Text). Observation was continued for 12 months.
Study endpoints and the evaluation of maximal vessel wall thickness, vessel wall area, and lumen area with MRI
The methodology for evaluating maximal vessel wall thickness, vessel wall area, and lumen area by using MRI has been reported previously 20 and is also described in the Supplemental Text.
We identified a plaque with the greatest maximal vessel wall thickness of the thoracic and abdominal aorta, respectively, as the representative plaque for each participant. The changes of these parameters (maximal vessel wall thickness, vessel wall area, and lumen area ) in all plaques of the thoracic and abdominal aortas and those in representative plaques of the both Participants in the combination-therapy group received both drugs for one year.
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by guest on April 19, 2017 http://circ.ahajournals.org/ Downloaded from aortas were measured. Therapeutic effectiveness was evaluated by the changes of the parameters in representative plaques, as well as by those in all plaques. In addition, we defined the percent change in maximal vessel wall thickness of representative plaques after 12 months of treatment as the primary endpoint. Also, we defined the percent change in vessel wall area and lumen area of representative plaques after 12 months of treatment as the secondary endpoints. The validity of the changes in representative plaques for the primary and secondary endpoints was proved in the preliminary trial and was described in the Supplemental Text.
All endpoints were assessed by an independent endpoint committee whose members were blinded to the treatment assignment.
Statistical Analysis
Based on a previous study 20 , a sample size of 34 patients per group was required to detect a mean difference of 13% in the percent change of maximal vessel wall thickness between the atorvastatin group and the combination-therapy group assuming a standard deviation of 15% and a power of 80% with 2-sided significant level of 0.05 using Dunnett's multiple comparison test.
The sample size of the etidronate group was set to be the same as that of the other groups. The intention-to-treat population, comprising all patients who underwent randomization and received at least one dose of a study drug, was used for the assessment of effectiveness and safety. The last observation carried forward method was used for participants who did not complete the follow-up period. If an additional treatment was initiated, according to the criteria mentioned in the Supplemental Text, the immediate examination must be performed and another examination at the regular 12-month timepoint. These results at two occasions are compared, and the worse value will be selected for the primary analysis. Differences between values at baseline and after 12 months were presented as means and standard errors or 95% CI for continuous variables.
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Results
Participants
From November 2009 to March 2011, we screened 178 patients with hypercholesterolemia. Of these patients, 70 patients were excluded for various reasons (see Table 1 shows the baseline characteristics of 108 participants. Participants had a mean age of 61 years and 42% were women. Baseline characteristics were well balanced between all three groups. . Other serum lipid and C-reactive protein levels were also significantly altered from baseline in both the combination-therapy and atorvastatin groups.
Baseline participant characteristics
Laboratory results
However, these variables for the most part remained unchanged in the etidronate group. On the other hand, in the combination-therapy group and the etidronate group, bone mineral density (BMD) levels were increased by 1.6% and 2.0% in lumber spine, 1.7% and 1.3% in femoral neck, respectively. However, in the atorvastatin group, these were not increased (-0.7% in lumber spine and -0.7% in femoral neck). Although pulse wave velocity (PWV) levels were not reduced significantly in all groups, these were marginally reduced in the combination-therapy group.
MRI results
At baseline, a total of 96 thoracic and 106 abdominal aortic plaques were detected in the combination-therapy group, 90 thoracic and 98 abdominal plaques in the atorvastatin group, and 94 thoracic and 105 abdominal plaques in the etidronate group. monotherapy successfully reduced plaques of the thoracic aorta, and the therapeutic effectiveness was almost equivalent. In contrast, etidronate monotherapy failed to induce atherosclerotic plaques regression in the thoracic aorta as compared with the comobination-therapy. These results were consistent with those of sensitivity analyses ( Supplemental Table 2A ).
In the abdominal aorta, maximal vessel wall thickness and vessel wall area, respectively, were reduced by 11.4% and 13.1% in the combination-therapy group, and by 5.5% and 6.2% in the etidronate group (combination-therapy vs. etironate; p=0.006 in maximal vessel wall thickness, p=0.001 in vessel wall area). In contrast, these parameters were only slightly altered by -0.9% and +2.3%, respectively, in the atorvastatin group (combination-therapy vs.
atorvastatin; p<0.001 in maximal vessel wall thickness, p<0.001 in vessel wall area). Lumen area in the abdominal aorta was increased by 6.5% and 2.8% in the combination-therapy and etidronate groups, respectively, but not (0.4%) in the atorvastatin group (combination-therapy vs. aorta, yet their reduction rates were significantly different. In contrast, atorvastatin monotherapy failed to induce atherosclerotic plaque regression in the abdominal aorta as compared with the comobination-therapy. These results were consistent with those of sensitivity analyses ( Supplemental Table 2B ).
Although Supplemental Table 1 illustrates the therapeutic effectiveness on representative plaques in the thoracic and abdominal aortas, we also evaluated that on all plaques in the both aortas, and obtained very similar trends (see Supplemental Table 3 ). The changes in representative plaques were tightly correlated with the changes in all plaques (see Supplemental Actually, we showed the change in atherosclerotic aortic plaques in MRI (Supplemental
Figure 3).
Regarding plaque characteristics, there were significantly more participants with calcified abdominal aortic plaques (31 out of 108; 28.7%) than those with calcified thoracic aortic plaques (15 out of 108; 13.9%) (p=0.008 by chi-square test).
In a post hoc analysis, we explored the influences of the existence of calcification in plaques on therapeutic effectiveness ( Table 3) Ac Ac Actu tu tual a a ly y, , w we we showed the change in athero ro rosc sclerotic aortic p p pla l qu ques es es i in MRI (Supplemental 
Adverse Events (Table4)
Adverse event and discontinuation rates in the combination-therapy group were comparable to those in other two groups: 4 (10.8%) and 2 (5.4%), respectively, out of 37 participants in the combination-therapy group; 4 (11.4%) and 1 (2.9%), respectively, out of 35 participants in the atorvastatin group; and 4 (11.1%) and 2 (5.6%), respectively, out of 36 participants in the etidronate group. Atorvastatin treatment was prone to higher liver enzyme levels, and etidronate treatment was prone to increased prevalence of gastrointestinal symptoms. However, a combination of both drugs did not exacerbate these symptoms.
Discussion
Our study demonstrated that combination-therapy with 20 mg of atorvastatin plus 400 mg of etidronate for 12 months reduced plaque size in both thoracic and abdominal aortas. Conversely, 20 mg of atorvastatin monotherapy reduced plaques only in the thoracic aorta, and 400 mg of etidronate monotherapy reduced plaques only in the abdominal aorta. This is the first randomized clinical trial to demonstrate that combination-therapy is significantly more effective than atorvastatin and etidronate monotherapy in reducing atherosclerotic aortic plaques.
In other clinical trials, atorvastatin or simvastatin treatment reduced LDL cholesterol (-47 to -38%) [2] [3] [4] , and maximal vessel wall thickness in the thoracic aorta (-12 to -9%). [2] [3] [4] Our atorvastatin and combination-therapy groups also showed similar reductions in LDL cholesterol (-41% and -39%, respectively) and maximal vessel wall thickness in the thoracic aorta (-12.3% reatment was prone to increased prevalence of gastrointestinal symptoms. Howe we eve ve er, r r a a a combination of both drugs did not exacerbate these symptoms.
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Ou Ou ur r r st st stud ud u y y y de de demo mon ns nstr tr t at ated ed t tha h t t co comb mb mbin in inat atio io i n-n-n-th th ther r rap The ineffectiveness of atorvastatin on abdominal aortic plaques might be a result of differences in the plaque constituents of thoracic and abdominal aortas. In the thoracic plaques, fatty streaks are common 5, 6 , whereas in the abdominal aorta, fibrous and calcified plaques are observed frequently. 5, 7 In fact, the prevalence of participants with calcified plaques in the abdominal aorta (28.7%, 31/108) was higher than that in the thoracic aorta (13.9%, 15/108) (p=0.008). Additionally, etidronate treatment resulted in a preferential regression of calcified plaques, while atorvastatin treatment demonstrated a preferential regression of non-calcified plaques.
Bisphosphonates are currently considered as the drug of choice for the prevention and treatment of osteoporosis and related fractures. 21 While, accumulating evidence suggests that bisphosphonates also have the potential to induce the regression of atherosclerotic plaques and vascular calcification in experimental studies [22] [23] [24] and small clinical studies. [14] [15] [16] They are grouped into two classes according to their chemical structure and the molecular mechanism by which they inhibit osteoclast activity. Members of the first generation of bisphosphonates are called "simple bisphosphonates" (clodronate and etidronate), while those of the secondary or newer generation are called "nitrogen-containing bisphosphonates". There is a significant fatty streaks are common 5, 6 , whereas in the abdominal aorta, fibrous and calcifie ie ed d d pl pl p aq aq aque ue ues s s ar ar a e e observed frequently. 5, 7 In fact, the prevalence of participants with calcified plaques in the ab bdo do domi mi mina na al l l ao ao aorta a (2 (2 (28. 8 7%, 31/108) was higher tha a an n n t th hat in the thor rac ac a ic a a aor or orta t (13.9%, 15/108) p p=0 =0 0.008). Add dd dit it itio o ona nall ll l y, y, , e e eti ti tidr dr dro on onat at te e e tr tre eat tm men n nt r resu u ult ted in in n a a p p pr re efe fer re ren nt ntia ial l l re egr gre es ess si sion on of f f ca ca alc cif if ifie ied d pl plaq aq aque ue ues, s, s, w whi hi hil le le a at t tor rv rvas as sta a ati tin n tr tr rea ea e tm tm tmen en ent t d de demo mo mon n nstr tr trat at a e ed ed a a p p pre e efe fe fer re rent nt ntia ial l l re re regr gr g e e ess si sion on n o of f f no no on-n-n-ca al l lci if fie ied d d plaques.
by guest on April 19, 2017 http://circ.ahajournals.org/ Downloaded from difference between "simple" and "nitrogen-containing" bisphosphonates. 25 Impressive regression of vascular calcification has been obtained with simple bisphosphonates, 14-16 but not the nitrogen-containing bisphosphonates. [17] [18] [19] Simple bisphosphonates directly inhibit metalloproteinases 26 and the expression of TNF-, a cytokine that promotes osteoblastic differentiation of vascular cells. 27 It also inhibits calcium deposition in the atheromatous lesions. 24 Simple bisphosphonates can be metabolized by phagocytes into non-hydrolysable adenine-containing analogues of ATP. 28 Intracellular accumulation of ATP analogues has been suggested to inhibit adenine nucleotide translocase, a component of the mitochondrial permeability transition pore, and thereby promote the activation of caspase-3 leading to apoptosis of macrophages and osteoclasts. 29 Hence, these cell types play a key role in the atherogenesis and calcification, and simple bisphosphonates might be able to suppress atherogenesis and calcification by several different mechanisms.
Calcified atherosclerotic plaques in the abdominal aorta were associated with the incidence of cardiovascular disease. [8] [9] [10] [11] Arterial calcification not only weakens vasomotor responses, but also affects atherosclerotic plaque stability. Emerging evidence suggests that atherosclerotic plaques with micro-calcifications located in thin fibrous cap are prone to rupture, particularly in regions with high background stress. [30] [31] [32] Therefore, the reduction and/or prevention of calcified atherosclerotic plaques in the aorta might be beneficial in reducing mortality due to cardiovascular disease.
A limitation of the present study is that it used the changes in aortic plaques as a surrogate for clinical endpoints. Currently, we are planning a large scale clinical trial that will assess the generalizability of our findings and establish the benefits of preventing cardiovascular events. In addition, since we did not set a placebo group in this study, we have no idea whether of caspase-3 leading to apoptosis of macrophages and osteoclasts. 29 Hence, these e e ce e el ll t typ yp ypes es es p p pla lay y a key role in the atherogenesis and calcification, and simple bisphosphonates might be able to u upp pp ppre re es ss ss a a ath th the er rog g gen en ene esis and calcification by seve e era ra r l different mech ch han a is sms ms ms.
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In conclusion, our data demonstrate that combination-therapy of atorvastatin and etidronate induced significant regression of atherosclerotic plaques in both the thoracic and abdominal aortas in patients with hypercholesterolemia at baseline. This approach was more effective in reducing atherosclerotic plaques in the abdominal aorta than atorvastatin or etidronate monotherapy. However, we have to conduct further study to evaluate whether these morphologic changes will be accompanied by changes in clinical events rates. In In Inte tera ra act ct ctio io ion n n 0.9
Thoracic aorta (n = 5 --* Numbers (%) of patients who had at least one event or an elevated value during the study period, with each event counted only once within a category. Patients could have more than one event in different categories. The denominators are the numbers of patients who received at least one dose of a study drug. † Frequencies of adverse events were compared between the combination-therapy group and the etidronate or atorvastatin monotherapy group with Fisher's exact test. ‡ This category includes patients whose alanine aminotransferase or aspartate aminotransferase levels were three or more times the upper limit of the normal range, and it is thought to attribute to study treatment. 99 0.99 9 9 t t re re re u u sult lt l in ng g in p per er erma ma m e ne n t nt n n nti ti u nu nuat at a io io ion n n of of of s s stu tu t dy dy t t tre reat at atme me ment nt 1 1 1 2 2 (2.9 .9 . ) ) 2 2 (5 (5 6 .6) ) 2 2 (5 (5 5.4 .4) ) ) . . Participants were ineligible if they met any of the following criteria: had participated in other investigational trials; had a history of taking anti-lipids drugs or bisphosphonates within past three months; were pregnant; had coronary, peripheral, or cerebrovascular disease; or had some types of a severe disease (e.g., renal insufficiency, hepatic insufficiency, terminal disease). In regards to the repeated MRI after 6 and 12 months of treatment, special attention was paid to matching the images to those at baseline. Since the aortas were located very close to the vertebrae, they do not usually move with respiration or bowel movements, and thus, the vertebrae, especially the ninth thoracic and fourth lumbar vertebrae, were used as the most important anatomic landmarks. To minimize submillimeter errors in image matching at different time points, three contiguous slices (i.e., no interslice gaps) were obtained, and the slice that most closely matched the one obtained at baseline was selected by using several anatomic landmarks (i.e., vertebrae, intercostal and lumbar arteries, pulmonary arteries and veins, and mesenteric arteries). The matching procedure was performed by two observers, who were blinded to the treatment assignment. The inter-observer agreement for the selection of the slice that most closely matched the one obtained at baseline was 98% (575 of 589 plaques), and any discrepancies were resolved by consensus.
2) Evaluation
Vessel wall area, maximal vessel wall thickness, and lumen area in each slice were measured three times by manual planimetry using the Digital Imaging and Communications in Medicine (DICOM) viewer (Synapse version 3.1.1.), and the averages of the three images were used for statistical analysis.
Lumen area and total vascular area were calculated from the traced luminal and outer wall boundaries.
Vessel wall thickness was calculated as the total vascular area minus the lumen area. All measurements were performed by one investigator, who was blinded to the treatment assignment.
Eight patients (24 thoracic and 30 abdominal aortic plaques) were randomly selected for intraobserver variability assessments. The image-specific error (SD between matched images) was 0.3 mm for aortic image. If maximal vessel wall thickness measurement values averaged over the 3 contiguous images, the error was reduced to 0.1 mm. This corresponds to an error of 2.8% for aortic plaques. On the basis of this reproducibility, we considered plaque size > 5.6% in aortic lesions to be accurately measured by MRI. The accuracy and reproducibility of this method was previously reported. [3] [4] [5] [6] Plaque characterization by using MRI was based on the signal intensities of plaques in T1W, T2W, and the transverse proton density-weighted (PDW) images. 7, 8 Lipid components were identified as hyperintense regions in T1W and PDW images and hypointense regions in T2W images. Fibrocellular components were hyperintense regions in all three images. Calcium deposits were hypointense regions in all the images. However, PDW images were omitted to reduce examination time in our study. Total examination time was about 40 min.
3) Follow-up procedures and additional treatment criteria
All participants were seen at 3-month intervals by their attending physicians. Body weight and blood pressure were measured, and blood and urine samples were taken for examination. The general health of each participant was assessed, the exercise and nutrition educations for health, especially for reducing serum lipids levels, were taught to each participant, and the results of the blood and urine examinations were explained by the physicians.
When LDL cholesterol levels reached > 200 mg/dl, participants in the combination-therapy and atorvastatin groups were initiated on ezetimibe and those in the etidronate group were initiated on atorvastatin. In the etidronate monotherapy group, when LDL cholesterol levels did not decrease by 10 mg/dl from baseline and by 5 mg/dl from those observed at the previous visit 3 months before, participants were initiated on atorvastatin. After initiation of atorvastatin, if LDL cholesterol levels reached > 200 mg/dl, the participants were additionally initiated on ezetimibe. When triglycerides levels were > 220 mg/dl, participants were initiated on fibrate in every group. When BMD was ≤ -2.5 SD, participants in the combination-therapy and etidronate groups were initiated on activated vitamin D 3 , and participants in the atorvastatin group were initiated on etidronate. When systolic blood pressure was > 140 mmHg, participants were initiated on anti-hypertensive drugs in every group. If participants were or became diabetic, then physicians could prescribe medicine at their judgment.
If the rate of aortic wall hyperplasia reaches >20%, participants in all groups will be initiated on warfarin.
If there were any severe side effects, treatment would be immediately terminated, and both blood samples and MRI would be acquired. The total study duration was 12 months. In the preliminary trial, we had hypothesized that the changes in maximal vessel wall thickness of representative plaques could determine the plaque regression effect, i.e., the primary endpoint, and had proved that the hypothesis was valid. Thus, we set the changes in maximal vessel wall thickness of representative plaques as the primary endpoint in the present study, and based on the abovementioned findings, the validity of that was proved again. 
4) Correlations between the changes of parameters in representative plaques and those in all plaques, and between the changes in maximal vessel wall thickness, vessel wall area, and lumen area
